EYEN vs. BOLT, VYNE, CARA, UNCY, NXTC, LEXX, SNSE, NBRV, DRRX, and JAN
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Bolt Biotherapeutics (BOLT), VYNE Therapeutics (VYNE), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), NextCure (NXTC), Lexaria Bioscience (LEXX), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), DURECT (DRRX), and JanOne (JAN). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Eyenovia presently has a consensus price target of $10.00, suggesting a potential upside of 1,196.51%. Bolt Biotherapeutics has a consensus price target of $7.00, suggesting a potential upside of 455.56%. Given Eyenovia's higher possible upside, analysts clearly believe Eyenovia is more favorable than Bolt Biotherapeutics.
Eyenovia received 89 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 65.00% of users gave Eyenovia an outperform vote.
In the previous week, Eyenovia and Eyenovia both had 3 articles in the media. Bolt Biotherapeutics' average media sentiment score of 1.26 beat Eyenovia's score of 0.22 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.
Eyenovia has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -878.58%. Bolt Biotherapeutics' return on equity of -51.18% beat Eyenovia's return on equity.
Eyenovia has higher earnings, but lower revenue than Bolt Biotherapeutics. Eyenovia is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 7.8% of Eyenovia shares are held by company insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eyenovia has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
Summary
Bolt Biotherapeutics beats Eyenovia on 8 of the 15 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
